Affordable Access

[Faecal occult blood test for colorectal cancer screening: high quality for a good price].

Authors
  • 1
  • 1 Rijksinstituut voor Volksgezondheid en Milieu, Centrum voor Bevolkingsonderzoek, Bilthoven, the Netherlands. [email protected] , (Netherlands)
Type
Published Article
Journal
Nederlands tijdschrift voor geneeskunde
1876-8784
Publication Date
Volume
157
Issue
16
Identifiers
PMID: 23594877
Source
Medline
License
Unknown

Abstract

The Dutch National Institute for Public Health and the Environment (RIVM) awarded the immunochemical faecal occult blood test (IFOBT) to FOB Gold of Sentinel following a European call for tenders. The contract-awarding procedure included the application of quality knock-out criteria, which were met by two suppliers. The decisive factor was the best price/quality ratio. A recent review indicated that, at present, no single IFOBT is better than any other. The decision to opt for a test manufactured by a different supplier than was used in the previous screening pilots made it necessary to re-determine the cut-off value. This value has now been set (88 ng/ml) and is confirmed by a laboratory test. Colonoscopy-related capacity planning, as well as its diagnostic yield, depends on numerous factors; therefore, the RIVM is currently monitoring the referral percentage and number of adenomas detected and is collaborating on quality terms. Any necessary adjustments are to be made during the introduction of the screening test.

Statistics

Seen <100 times